Literature DB >> 16522834

Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma.

Jaya D Chidambaram1, Wondu Alemayehu, Muluken Melese, Takele Lakew, Elizabeth Yi, Jenafir House, Vicky Cevallos, Zhaoxia Zhou, Kathryn Maxey, David C Lee, Brett L Shapiro, Muthiah Srinivasan, Travis Porco, John P Whitcher, Bruce D Gaynor, Thomas M Lietman.   

Abstract

CONTEXT: The World Health Organization recommends mass antibiotic distributions in its strategy to eliminate blinding trachoma as a public health concern. Some hypothesize that a single distribution is sufficient to control the ocular strains of chlamydia that cause trachoma. Others believe infection will inevitably return and periodic treatments or other measures are essential.
OBJECTIVE: To determine whether ocular chlamydial infection returns to the community up to 24 months after a single mass antibiotic distribution in a hyperendemic region of Ethiopia. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal cohort study conducted March 2003 to March 2005 in the Gurage Zone of Ethiopia. Eight randomly selected villages were assessed for ocular chlamydial infection. Fifteen untreated villages were randomly chosen at 12 months to allow assessment of a secular trend. INTERVENTION: A single dose of oral azithromycin was offered to all residents of the 8 selected villages who were aged 1 year or older. MAIN OUTCOME MEASURE: Prevalence of ocular chlamydial infection in all children aged 1 to 5 years from each intervention village prior to treatment and 2, 6, 12, 18, and 24 months after mass antibiotic treatment, and also in untreated villages enrolled at 12 months.
RESULTS: Five hundred fifteen children were examined for ocular chlamydial infection at baseline. For the follow-up examinations, the mean participation rate was 83%. The mean prevalence of infection in children aged 1 to 5 years decreased from 43.5% (95% confidence interval [CI], 35.0%-52.0%) to 5.1% (95% CI, 1.1%-9.2%) after treatment. On average, infection returned gradually over 24 months to 11.3% (95% CI, 4.5%-18.1%; P = .001). In 7 of 8 villages, infection was higher at 24 months than at 2 months. In the remaining village, no infection could be identified at any point after treatment. Villages enrolled at 12 months had significantly fewer infections than those enrolled 12 months earlier, suggesting a secular trend (P<.001).
CONCLUSIONS: Ocular chlamydial infection was not eliminated in children aged 1 to 5 years after a single mass azithromycin distribution; it slowly returned over 24 months, although not to baseline levels. Repeated treatments or other effective measures will be necessary for elimination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522834     DOI: 10.1001/jama.295.10.1142

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  69 in total

1.  Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Authors:  H R Wright; J E Keeffe; H R Taylor
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

2.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  Trachoma: ancient scourge, disease elimination, and future research.

Authors:  Charles Knirsch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

4.  Childhood mortality in a cohort treated with mass azithromycin for trachoma.

Authors:  Jeremy D Keenan; Berhan Ayele; Teshome Gebre; Mulat Zerihun; Zhaoxia Zhou; Jenafir I House; Bruce D Gaynor; Travis C Porco; Paul M Emerson; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

Review 5.  Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis.

Authors:  D Dean
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

6.  Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

7.  Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden.

Authors:  Peter J Hotez; Aruna Kamath
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

8.  Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma.

Authors:  Kevin Cyrus Hong; Julius Schachter; Jeanne Moncada; Zhaoxia Zhou; Jenafir House; Thomas M Lietman
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

9.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.